Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Treatment of Coats' disease with intravitreal bevacizumab.
[coats disease]
To
compare
the
efficacy
of
intravitreal
bevacizumab
plus
ablative
therapy
with
ablative
therapy
alone
for
Coats
'
disease
.
A
retrospective
review
of
all
paediatric
patients
who
received
treatment
for
Coats
'
disease
from
a
single
surgeon
(
GBH
)
from
1
January
2001
to
31
March
2010
was
performed
.
Ten
consecutive
patients
who
received
intravitreal
bevacizumab
as
part
of
their
treatment
were
matched
to
10
patients
treated
with
ablative
therapy
alone
by
macular
appearance
,
quadrants
of
subretinal
fluid
,
and
quadrants
of
telangiectasias
.
Outcomes
evaluated
were
number
of
treatment
sessions
,
time
to
full
treatment
,
and
resolution
of
disease
.
There
was
no
statistical
difference
between
baseline
characteristics
when
comparing
the
bevacizumab
and
control
groups
.
Eyes
treated
with
bevacizumab
required
more
treatments
over
a
longer
time
period
compared
to
the
control
group
.
All
patients
in
the
bevacizumab
group
were
successfully
treated
while
two
of
the
patients
in
the
control
group
failed
ablative
techniques
.
Intravitreal
bevacizumab
may
play
a
role
as
adjuvant
therapy
in
select
cases
of
Coats
'
disease
,
but
its
use
does
not
reduce
the
time
to
full
treatment
.
Resolution
of
disease
was
seen
in
the
most
severe
cases
treated
with
bevacizumab
plus
thermal
ablation
whereas
their
matched
controls
failed
therapy
with
laser
and
cryotherapy
alone
.
Diseases
Validation
Diseases presenting
"single surgeon"
symptom
achondroplasia
coats disease
trochlear dysplasia
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom
